Cutaneous Lymphoma, Leukemia, and Related Disorders

Skin Cancer: Recognition and Management, Second Edition

Volumn , Issue , 2008, Pages 238-266

  Burg, Güunter ^a   Kempf, Werner ^a,b   Dummer, Reinhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Kempf und Pfaltz Histologische Diagnostik   (Switzerland)

Author keywords

Classification systems; Cutaneous lymphoma; Diagnostic tools; Epidemiology; Leukemia

Indexed keywords

EID: 77949901786     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470696347.ch15     Document Type: Chapter

References (167)

1. Alibert JLM. Tableau du pian fongoide. Description des maladies de la peau, observées à l'Hôpital Saint-Louis et exposition des meilleurs méthodes suivies pour leur traitement. Paris: Barrois L'Ainé & Fils; 1806.
2. Bontius J. De medidna indorum libri IV. Piso; 1642.
3. Brouet JC, Flandrin G, Seligmann M. Indications of the thymus-derived nature of the proliferating cells in six patients with Sezary's syndrome. N Engl J Med 1973;289:341-4.
4. Burg G, Braun-Falco O. Classification and differentiation of cutaneous lymphomas. Enzyme-cytochemical and immunocytological studies. Br J Dermatol 1975;93:597-9.
5. Burg G, Braun-Falco O. Morphological and functional differentiation and classification of cutaneous lymphomas. Bull Cancer 1977;64:225-40.
6. Kerl H, Cerroni L. Primary cutaneous B-cell lymphomas: then and now. J Cutan Pathol 2006;33 Suppl 1 :1-5.
7. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999;89:1240-4.
8. Greene MH, Dalager NA, Lamberg SI, et al. Mycosis fungoides: epidemiologic observations. Cancer Treat Rep 1979;63:597-606.
9. Cohen SR, Stenn KS, Braverman IM, et al. Clinico-pathologic relationships, survival, and therapy in 59 patients with observations on occupation as a new prognostic factor. Cancer 1980;46:2654-66.
10. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 1989;81:1560-7.
11. Teixeira F, Ortiz PA, Cortes FR, et al. Do environmental factors play any role in the pathogenesis of mycosis fungoides and Sezary syndrome? Int J Dermatol 1994;33:770-2.
12. Samman PD. The natural history of parapsoriasis en plaques (chronic superficial dermatitis) and preretic-ulotic poikiloderma. Br J Dermatol 1972;87:405-11.
13. Weinstock MA. Epidemiology of mycosis fungoides. Semin Dermatol 1994;13:154-9.
14. Kumar R, Xiu Y, Zhuang HM, et al. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. Br JDermatol 2006;155:357-63.
15. Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006;142:577-84.
16. Bazin P. Leçons sur le traitement des maladies chroniques en général, affections de la peau en particulier, par l'emploi comparé des eaux minérales, de l'hydrothérapie et des moyens pharmaceutiques. Paris: Delahaye; 1870.
17. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979;63:725-8.
18. Olsen E, Vonderheid E, Pimpinelli E, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC) [published online ahead of print on May 31, 2007]. Blood.
19. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:479-84.
20. Schmid MH, Bird P, Dummer R, et al. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept. Arch Dermatol 1999;135:1204-8.
21. Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 2002;138:42-8.
22. Cerroni L, Volkenandt M, Rieger E, et al. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol 1994;102:231-5.
23. Beylot-Barry M, Lamant L, Vergier B, et al. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 1996;149:483-92.
24. Cerroni L, Minkus G, Putz B, et al. Laser beam microdissection in the diagnosis of cutaneous B-cell lymphoma. Br JDermatol 1997;136:743-6.
25. Kempf W, Cozzio A, Kazakov DV, et al. Cytogenetic studies in cutaneous lymphomas. In: Burg G, Kempf W, editors. Cutaneous lymphomas. Boca Raton: Francis & Taylor Group; 2005. p. 69-72.
26. Storz MN, van de Rijn M, Kim YH, et al. Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol 2003;120:865-70.
27. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005;105:3671-8.
28. Burg G, Dummer R, Kerl H. Classification of cutaneous lymphomas. Dermatol Clin 1994;12:213-7.
29. Burg G, Jaffe ES, Kempf W, et al. WHO/EORTC classification of cutaneous lymphomas. In: LeBoit P, Burg G, Weedon D, et al., editors. WHO Books: Tumors of the skin, vol. X. Lyon: WHO IARC; 2006. p. 166-8.
30. Burg G, Kempf W, Hess Schmid M. Prognostic parameters in cutaneous lymphomas. In: Burg G, Kempf W, editors. Cutaneous lymphomas. Boca Raton: Francis & Taylor Group; 2005. p. 529-42.
31. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85.
32. LeBoit P Burg G, Weedon D, et al., editors. Tumors of the skin, vol. X. Lyon: WHO IARC; 2006.
33. Bahler DW, Kim BK, Gao A, et al. Analysis of immunoglobulin V genes suggests cutaneous marginal zone B-cell lymphomas recognise similar antigens. Br J Haematol 2006;132:571-5.
34. Santucci M, Burg G, Feller AC. Interrater and intrarater reliability of histologic criteria in early cutaneous T-cell lymphoma: an EORTC Cutaneous Lymphoma Project Group study. Dermatol Clin 1994; 12:323-7.
35. Smoller BR, Detwiler SP, Kohler S, et al. Role of histology in providing prognostic information in mycosis fungoides. J Cutan Pathol 1998;25:311-5.
36. Smoller BR, Bishop K, Glusac E, et al. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol 1995;19:1423-30.
37. Massone C, Kodama K, Kerl H, et al. Histopathologic features of early (patch) lesions of mycosis fun-goides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005;29:550-60.
38. Santucci M, Biggeri A, Feller AC, et al. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC Cutaneous Lymphoma Study Group investigation. European Organization for Research and Treatment of Cancer. Am J Surg Pathol 2000;24:40-50.
39. Guitart J, Kennedy J, Ronan S, et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol 2001;28:174-83.
40. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053-63.
41. Dummer R, Kohl O, Gillessen J, et al. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch Dermatol 1993;129:433-6.
42. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994;103:669-73.
43. Woringer F, Kolopp P. Lesion erythemato-squameuse polycyclique de l'avant-bras evoluant depuis 6 ans chez un garconnet de 13 ans. Ann Dermatol Syphilol 1939;10:945-58.
44. Fujiwara Y, Abe Y, Kuyama M, et al. CD8+ cutaneous T-cell lymphoma with pagetoid epidermotropism and angiocentric and angiodestructive infiltration. Arch Dermatol 1990;126:801-4.
45. Burg G, Schmockel C. Syringolymphoid hyperplasia with alopecia-a syringotropic cutaneous T-cell lymphoma? Dermatology 1992;184:306-7.
46. Cerroni L, Kerl H. Primary follicular mucinosis and association with mycosis fungoides and other cutaneous T-cell lymphomas. J Am Acad Dermatol 2004;51:146-7; author reply 7-8.
47. Cerroni L, Fink-Puches R, Back B, et al. Follicular mucinosis: a critical reappraisal of clinicopatho-logic features and association with mycosis fungoides and Sezary syndrome. Arch Dermatol 2002;138:182-9.
48. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinico-pathologic and follow-up study of 51 patients. Arch Dermatol 2002;138:191-8.
49. Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol 2004;18:397-415.
50. Camacho FM, Burg G, Moreno JC, et al. Granulomatous slack skin in childhood. Pediatr Dermatol 1997;14:204-8.
51. Convit J, Kerdel F, Goihman M, et al. Progressive, atrophying, chronic granulomatous dermohy-podermitis. Autoimmune disease? Arch Dermatol 1973;107:271-4.
52. LeBoit PE. Granulomatous slack skin. Dermatol Clin 1994;12:375-89.
53. LeBoit PE, Beckstead JH, Bond B, et al. Granulomatous slack skin: clonal rearrangement of the T-cell receptor beta gene is evidence for the lymphoprolifera-tive nature of a cutaneous elastolytic disorder. J Invest Dermatol 1987;89:183-6.
54. vonZumbusch L. Fallbericht. Arch Dermatol Syphilol 1915;51:119.
55. Sezary A, Bouvrain Y. Erythrodermie avec presence de cellules monstueuses dansle dermeetlesang circulant. Bull Soc Fr Dermatol Syphiligr 1938;45:254-60.
56. Baccaredda A. Reticulohistiocytosis cutanea hyper-plastica benigna cum melanodermia. Arch Dermatol Syphilol 1939;179:209-56.
57. Kerl H, Aubock L, Bayer U. [Formation and treatment of pathologic scars-clinical and micromor-phologic investigations (author's transl)]. Z Hautkr 1981;56:282-300.
58. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106.
59. Vonderheid EC, Pena J, Nowell P. Sezary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma 2006;47:1841-56.
60. Dummer R, Posseckert G, Nestle F, et al. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? J Invest Dermatol 1992;98:50-4.
61. Vowels BR, Cassin M, Vonderheid EC, et al. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90-4.
62. Trotter MJ, Whittaker SJ, Orchard GE, et al. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol 1997;24:286-91.
63. Kamarashev J, Burg G, Kempf W, et al. Comparative analysis of histological and immunohistological features in mycosis fungoides and Sezary syndrome. J Cutan Pathol 1998;25:407-12.
64. Harmon CB, Witzig TE, Katzmann JA, et al. Detection of circulating T cells with CD4+CD7-immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 1996;35:404-10.
65. Klemke CD, Fritzsching B, Franz B, et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006;20:1123-9.
66. Scarisbrick JJ, Woolford AJ, Russell-Jones R, et al. Allelotyping in mycosis fungoides and Sezary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. J Invest Dermatol 2001;117:663-70.
67. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995;13:1343-54.
68. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the longterm follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-61.
69. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign-histologically malignant. Arch Dermatol 1968;97:23-30.
70. Gruber R, Sepp NT, Fritsch PO, et al. Prognosis of lymphomatoid papulosis. Oncologist 2006;11:955-7; author reply 7.
71. Kadin M, Nasu K, Sako D, et al. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol 1985;119:315-25.
72. Kaudewitz P, Burg G, Stein H, et al. Monoclonal antibody patterns in lymphomatoid papulosis. Dermatol Clin 1985;3:749-57.
73. Davis TH, Morton CC, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 1992;326:1115-22.
74. Amagai M, Kawakubo Y, Tsuyuki A, et al. Lym-phomatoid papulosis followed by Ki-1 positive anaplastic large cell lymphoma: proliferation of a common T-cell clone. JDermatol 1995;22:743-6.
75. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95.
76. Herbst H, Sander C, Tronnier M, et al. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br JDermatol 1997;137:680-6.
77. Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med 1991;325:1078-81.
78. Mehregan DA, Su WP, Kurtin PJ. Subcutaneous T-cell lymphoma: a clinical, histopathologic, and im-munohistochemical study of six cases. J Cutan Pathol 1994;21:110-7.
79. Salhany KE, Macon WR, Choi JK et al. Subcutaneous panniculitis-like T-cell lymphoma: clinico-pathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998;22:881-93.
80. Gonzalez CL, Medeiros LJ, Braziel RM, et al. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991;15:17-27.
81. Perniciaro C, Zalla MJ, White JW Jr, et al. Subcutaneous T-cell lymphoma. Report of two additional cases and further observations. Arch Dermatol 1993;129:1171-6.
82. Lozzi GP, Massone C, Citarella L, et al. Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol 2006;28:9-12.
83. Weenig RH, Ng CS, Perniciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol 2001;23:206-15.
84. Bekkenk MW, Vermeer MH, Jansen PM, et al. Periph-eral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003;102:2213-9.
85. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003;97:610-27.
86. Iwatsuki K, Ohtsuka M, Harada H, et al. Clinicopatho-logic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol 1997;133:1081-6.
87. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clin-icopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002;10:7-14.
88. Levine PH, Jaffe ES, Manns A, et al. Human T-cell lymphotropic virus type I and adult T-cell leukemia/lymphoma outside Japan and the Caribbean Basin. Yale J Biol Med 1988;61:215-22.
89. D'Incan M, Antoniotti O, Gasmi M, et al. HTLV-I-associated lymphoma presenting as mycosis fun-goides in an HTLV-I non-endemic area: a viro-molecular study. Br J Dermatol 1995;132:983-8.
90. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006;24:1376-82.
91. Cerroni L, Signoretti S, Hofler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997;21:1307-15.
92. Bailey EM, Ferry JA, Harris NL, et al. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol 1996;20:1011-23.
93. Pimpinelli N, Santucci M. The skin-associated lymphoid tissue-related B-cell lymphomas. Semin Cutan Med Surg 2000;19:124-9.
94. Braun-Falco O, Guggenberger K, Burg G, et al. [Im-munocytoma simulating chronic acrodermatitis atrophicans]. Hautarzt 1978;29:644-7.
95. Garbe C, Stein H, Gollnick H, et al. [Cutaneous B cell lymphoma in chronic Borrelia burgdorferi infection. Report of 2 cases and a review of the literature]. Hautarzt 1988;39:717-26.
96. LeBoit PE, McNutt NS, Reed JA, et al. Primary cutaneous immunocytoma. A B-cell lymphoma that can easily be mistaken for cutaneous lymphoid hyperplasia. Am J Surg Pathol 1994;18:969-78.
97. Tomaszewski MM, Abbondanzo SL, Lupton GP. Ex-tranodal marginal zone B-cell lymphoma of the skin: a morphologic and immunophenotypic study of 11 cases. Am J Dermatopathol 2000;22:205-11.
98. Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993;23:117-25.
99. Child FJ, Woolford AJ, Calonje E, et al. Molecular analysis of the immunoglobulin heavy chain gene in the diagnosis of primary cutaneous B cell lymphoma. J Invest Dermatol 2001;117:984-9.
100. Pimpinelli N, Santucci M, Bosi A, et al. Primary cutaneous follicular centre-cell lymphoma-a lympho-proliferative disease with favourable prognosis. Clin Exp Dermatol 1989;14:12-9.
101. Rijlaarsdam JU, Meijer CJ, Willemze R. Differentiation between lymphadenosis benigna cutis and primary cutaneous follicular center cell lymphomas. A comparative clinicopathologic study of 57 patients. Cancer 1990;65:2301-6.
102. Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 2000;95:3922-8.
103. Bergman R, Kurtin PJ, Gibson LE, et al. Clinico-pathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma. Arch Dermatol 2001;137:432-9.
104. Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 2002;20:647-55.
105. Berti E, Alessi E, Caputo R, et al. Reticulohistiocytoma of the dorsum. J Am Acad Dermatol 1988;19:259-72.
106. Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005;106:2491-7.
107. Paulli M, Viglio A, Vivenza D, et al. Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. Hum Pathol 2002;33:937-43.
108. Sundram U, Kim Y, Mraz-Gernhard S, et al. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol 2005;32:227-34.
109. Gronbaek K, Moller PH, Nedergaard T, et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br J Dermatol 2000;142:913-23.
110. Dijkman R, Tensen CP, Buettner M, et al. Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID. Blood 2006;107:4926-9.
111. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988;12:433-43.
112. Dommann SN, Dommann-Scherrer CC, Zimmerman D, et al. Primary cutaneous T-cell-rich B-cell lymphoma. A case report with a 13-year follow-up. Am J Dermatopathol 1995;17:618-24.
113. Pfleger L, Tappeiner J. [On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis)]. Hautarzt 1959;10:359-63.
114. Perniciaro C, Winkelmann RK, Daoud MS, et al. Malignant angioendotheliomatosis is an angiotropic intravascular lymphoma. Immunohistochemical, ul-trastructural, and molecular genetics studies. Am J Dermatopathol 1995;17:242-8.
115. Ferreri AJ, Campo E, Seymour JF, et al. Intravascu-lar lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004;127:173-83.
116. Liebow AA, Carrington CR, Friedman PJ. Lym-phomatoid granulomatosis. Hum Pathol 1972;3:457-558.
117. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958;46:218-23.
118. Jacobson MA, Hutcheson AC, Hurray DH, et al. Cutaneous involvement by Burkitt lymphoma. J Am Acad Dermatol 2006;54:1111-3.
119. Motegi S, Okada E, Nagai Y, et al. Skin manifestation of mantle cell lymphoma. Eur J Dermatol 2006;16:435-8.
120. Waldenstroem J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia-new syndrome? Acta Medica Scand 1944;117:216-47.
121. Mascaro JM, Montserrat E, Estrach T, et al. Specific cutaneous manifestations of Waldenstrom's macroglobulinaemia. A report of two cases. Br J Dermatol 1982;106:217-22.
122. Libow LF, Mawhinney JP, Bessinger GT. Cutaneous Waldenstrom's macroglobulinemia: report of a case and overview of the spectrum of cutaneous disease. J Am Acad Dermatol 2001;45:S202-6.
123. Requena L, Sarasa JL, Ortiz Masllorens F, et al. Follicular spicules of the nose: a peculiar cutaneous manifestation of multiple myeloma with cryoglobulinemia. J Am Acad Dermatol 1995;32:834-9.
124. Martin JM, Nicolau MJ, Galan A, et al. CD4+/CD56+ haematodermic neoplasm: a preculsor haematologi-cal neoplasm that frequently first presents in the skin. J Eur Acad Dermatol Venereol 2006;20:1129-32.
125. Dummer R, Potoczna N, Haffner AC, et al. A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Arch Dermatol 1996;132:550-3.
126. Kato N, Yasukawa K, Kimura K, et al. CD2-CD4+ CD56+hematodermic/hematolymphoid malignancy. J Am Acad Dermatol 2001;44:231-8.
127. Ng AP, Lade S, Rutherford T, et al. Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. Haematologica 2006;91:143-4.
128. Assaf C, Gellrich S, Whittaker S, et al. CD56 lym-phoproliferative disorders of the skin: A multicenter study of the Cutaneous Lymphoma Project Group of the European Organization for Research and Treatment of Cancer (EORTC) [published online ahead of print on October 3, 2006]. J Clin Pathol.
129. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005;123:662-75.
130. Petrella T, Comeau MR, Maynadie M, et al. "Agranular CD4+ CD56+ hematodermic neoplasm" (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852-62.
131. Lin P, Jones D, Dorfman DM, et al. Precursor B-cell lymphoblastic lymphoma: a predominantly extran-odal tumor with low propensity for leukemic involvement. Am J Surg Pathol 2000;24:1480-90.
132. Perifanis V, Sfikas G, Tziomalos K, et al. Skin involvement in Hodgkin's disease. Cancer Invest 2006;24:401-3.
133. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkin's disease. Int J Dermatol 2006;45:251-6.
134. Jurisic V, Bogunovic M, Colovic N, et al. Indolent course of the cutaneous Hodgkin's disease. J Cutan Pathol 2005;32:176-8.
135. Biberstein H. Lymphozytome. Zentralbl Hautkr 1923;6:70-1.
136. Bafverstedt B. Can benign lymphadenosis (lymphomatosis) of the orbit occasionally be a para-neoplasia? Acta Ophthalmol (Copenh) 1974;52: 367-72.
137. Caro WA, Helwig HB. Cutaneous lymphoid hyperplasia. Cancer 1969;24:487-502.
138. Brocq L. Les erythrodermies pityriasiques en plaques disséminées. Rev Gen Clin J Pract 1897;11:577-90.
139. Brocq L. Les parapsoriasis. Ann Dermatol Syphilol 1902;3:433-68.
140. Burg G, Kempf W, Dummer R, et al. Parapsoriasis. In: Burg G, Kempf W, editors. Cutaneous lymphomas. Boca Raton: Francis & Taylor Group; 2005. p. 351-4.
141. Buechner SA, Su DWP. Skin involvement in leukemias. In: Burg G, Kempf W, editors. Cutaneous lymphomas. Boca Raton: Francis & Taylor Group; 2005. p. 373-405.
142. Thestrup-Pedersen K, Kaltoft K. Genotraumatic T cells and cutaneous T-cell lymphoma. A causal relationship? Arch Dermatol Res 1994;287:97-101.
143. Blauvelt A, Asada H, Klaus-Kovtun V, et al. Interleukin-15 mRNA is expressed by human ker-atinocytes Langerhans cells, and blood-derived dendritic cells and is downregulated by ultraviolet B radiation. J Invest Dermatol 1996;106:1047-52.
144. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-8.
145. Dobbeling U, Dummer R, Laine E, et al. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998;92:252-8.
146. Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 1995;22:11-7.
147. Taylor RS, Ramirez RD, Ogoshi M, et al. Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 1996;106:759-65.
148. Yamanaka K, Clark R, Dowgiert R, et al. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 2006;12:376-82.
149. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
150. Vonderheid EC, Micaily B. Treatment of cutaneous T-cell lymphoma. Dermatol Clin 1985;3:673-87.
151. Dummer R, Cozzio A, Urosevic M. Pathogenesis and therapy of cutaneous lymphomas-progress or impasse? Exp Dermatol 2006;15:392-400.
152. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006;42:1014-30.
153. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
154. Foss FM. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann N Y Acad Sci 2001;941:166-76.
155. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006;33:S11-6.
156. Duvic M, Talpur R, Ni X, et al. Phase II Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory Cutaneous T-cell Lymphoma (CTCL). Blood 2006:109:31-9.
157. Coors EA, Schuler G, Von Den Driesch P. Topical im-iquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol 2006;16:391-3.
158. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005;106:454-7.
159. Stadler R, Kremer A. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rex-inoids. Semin Oncol 2006;33:S7-10.
160. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-52.
161. Heinzerling L, Dummer R, Kempf W, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol 2000;136:374-8.
162. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003;71:250-6.
163. Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol 2006;33:S44-52.
164. Hagberg H, Pettersson M, Bjerner T, et al. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol 2005;22:191-4.
165. Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995;154:1491-8.
166. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003;17:1435-48, ix.
167. Kunzi V, Oberholzer PA, Heinzerling L, et al. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. J Invest Dermatol 2006;126:2525-32.